glp-1 discontinuation rates New Truveta study highlights patterns of Most Patients Discontinue GLP-1 Drugs

This variability emphasizes the need for personalized medicine, where Se therapy is tailored according to an individuals genetic makeup, metabolic profile, and thyroid health status [103]

Science 1987

These shifts drive both weight regain and a loss of glycemic control

A second patient on commercial therapy with BardetBiedl syndrome, fair skin (Fitzpatrick skin type II), and a skin examination revealing extensive chronic UVrelated damage who lived on an island close to the equator experienced increased pigmentation of the skin and existing melanocytic nevi and was diagnosed with stage pT1a superficial spreading melanoma after 6 months of setmelanotide treatment

This insight helps your clinician optimize your injection schedule and site selection for your unique peptide-pathway biology